PACB today
$1.96-$0.01 (-0.76%)close Nov 13, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourLeaning Bullish
15 minSymmetric Triangle
5 minStrong Bearish
Daily trend turns down below $1.07
Key levels
Resistance$2.40
Resistance$1.97
Support$1.61
Support$1.25
Latest news & SEC filings
DealPacific Biosciences of California, Inc. plans $100M stock sale via ATM program
DealPacific Biosciences to raise up to $100M selling shares via Allen & Co. program
All PACB news →About Pacific Biosciences
Pacific Biosciences designs and builds DNA sequencing instruments and related consumables based on its Single-Molecule Real-Time technology, which reads long stretches of genetic material with high accuracy. Its Revio, Vega, and Sequel platforms, together with SMRT Cells and reagent kits, support work in human genetics, cancer research, infectious disease, and crop and livestock science. Buyers include university and government researchers, clinical and testing laboratories, drugmakers, and agricultural firms. The company sells directly and through distributors across North America, Europe, Asia, the Middle East, Africa, and Latin America.
Based on the company's 10-K filed Feb 25, 2026.
Nasdaq · Technology
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
What Is the Price Target for PACB?
SEPT Low Target
$1.22
SEPT Mid Target
$1.43
SEPT High Target
$1.64
Analyst Consensus
$1.43
Is PACB a Buy or Sell Right Now?
Thesis
- •Revenue growing 3.9% YoY with STABLE trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PACB.
Start Free Trial →Is PACB Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
Analyst Consensus
Fair Value
$1.43
19
Moat Score
NONE
3/9
Piotroski Score
-5.9
Altman Z-Score
What Is Smart Money Doing with PACB?
Insider Signal
SELLING
0 buys / 11 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Gibson James R II | officer | Buy | 500,000 | $590K | Oct 6, 2026 |
| Gibson James R II | officer | Sale | 661,815 | $2.1M | Oct 6, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PACB Growth Story
Revenue YoY
3.9%
3yr Revenue CAGR
7.6%
EPS Growth YoY
-14.47%
FCF Growth YoY
46.3%
Revenue Trend
STABLE
Dark Pool Trades for PACB
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PACB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:53:52 | $1.96 | 2,878 | $$6K | MIDPOINT |
| 20:53:52 | $1.96 | 1,200 | $$2K | MIDPOINT |
| 20:53:50 | $1.96 | 1,900 | $$4K | BUY |
| 20:53:41 | $1.96 | 2,000 | $$4K | MIDPOINT |
| 20:52:35 | $1.96 | 4,600 | $$9K | BUY |
5 dark pool trades shown · $$25K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for PACB
PREVIEWSEPT Investing provides real-time options flow tracking for PACB, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $1.5 | Dec 18 | 35 | $$55 | 1 | SWEEP |
| CALL | $1.5 | Dec 18 | 35 | $$440 | 8 | SWEEP |
| CALL | $1.5 | Dec 18 | 35 | $$110 | 2 | SWEEP |
| CALL | $1.5 | Dec 18 | 35 | $$55 | 1 | SWEEP |
| CALL | $1.5 | Dec 18 | 35 | $$55 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PACB — frequently asked questions
What is PACB stock price today?
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) is at $1.96, down 0.76% (-$0.01) at the Nov 13, 2026 close.
Why is PACB stock moving today?
Latest PACB news — Nov 11, 2026: Pacific Biosciences of California, Inc. plans $100M stock sale via ATM program · Nov 10, 2026: Pacific Biosciences to raise up to $100M selling shares via Allen & Co. program
What is the PACB price target?
The average analyst price target for PACB is $1.43, ranging from $1 to $2, based on 2 analysts.
What do analysts rate PACB?
Analyst ratings for PACB: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did PACB beat earnings?
PACB last reported on Aug 5, 2026: EPS -$0.14 vs -$0.13 expected — a miss of 9.4%.
Does PACB pay a dividend?
PACB does not currently pay a dividend.
What are PACB support and resistance levels?
Support: $1.61, $1.25. Resistance: $1.97, $2.40, $2.73.
What are insiders doing with PACB?
Insider activity: SELLING, 0 buys and 11 sells in the last 90 days.
What is the latest news on PACB?
Nov 11, 2026: Pacific Biosciences of California, Inc. plans $100M stock sale via ATM program · Nov 10, 2026: Pacific Biosciences to raise up to $100M selling shares via Allen & Co. program